Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
12 August 2004Website:
http://www.stereotaxis.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:05:02 GMTDividend
Analysts recommendations
Institutional Ownership
STXS Latest News
Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union's new Medical Device Regulation (MDR) regulatory framework. The recertification under MDR covers all Stereotaxis devices currently available in Europe.
Stereotaxis offers a cutting-edge proposal that utilizes advanced robotic technology and telerobotic presence to provide high-quality cardiac ablation services in a sustainable manner.
The acquisition of Access Point Technologies by Stereotaxis (STXS) is expected to enhance its presence in the catheter market.
Stereotaxis, Inc. (NYSE:STXS) Q1 2024 Earnings Conference Call on May 13, 2024 at 4:30 PM ET, with speakers including David Fischel, Chairman and CEO, and Kimberly Peery, CFO. Participants include Frank Takkinen, Jason Wittes, Adam Maeder, Joshua Jennings. Thank you for joining us.
Major Regulatory Approvals Coming For Stereotaxis In The Next 10 Months
Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.
ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 fourth quarter and full year ended December 31, 2023 on Monday, March 4, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments.
Stereotaxis was forced to do a human trial for its Magic catheter before it can get CE Mark. This is starting in a few weeks. Stereotaxis will soon submit a PMA for FDA approval of the Magic catheter 180 days after submission. China is set to approve Genesis in Q1 of next year.
ST. LOUIS, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 third quarter on Thursday, November 9, 2023 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company's results and corporate developments.
What type of business is Stereotaxis?
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
What sector is Stereotaxis in?
Stereotaxis is in the Healthcare sector
What industry is Stereotaxis in?
Stereotaxis is in the Medical Instruments & Supplies industry
What country is Stereotaxis from?
Stereotaxis is headquartered in United States
When did Stereotaxis go public?
Stereotaxis initial public offering (IPO) was on 12 August 2004
What is Stereotaxis website?
https://www.stereotaxis.com
Is Stereotaxis in the S&P 500?
No, Stereotaxis is not included in the S&P 500 index
Is Stereotaxis in the NASDAQ 100?
No, Stereotaxis is not included in the NASDAQ 100 index
Is Stereotaxis in the Dow Jones?
No, Stereotaxis is not included in the Dow Jones index
When does Stereotaxis report earnings?
The next expected earnings date for Stereotaxis is 09 August 2024